Better Medication Management and Compliance
Curant Health (Formerly HealthStat Rx) is a national healthcare company utilizing an innovative patient-centric services, medication management and specialty pharmacy program to provide chronic disease expertise and support to improve the therapy experience and quality of life for patients nationwide. Curant Health also provides hospitals, Accountable Care Organizations, concierge medicine practices, benefits managers, self insured employers, health care technology and home healthcare companies support programs to dramatically improve patient outcomes, reduce the health care spend, and decrease hospital readmission rates.
Curant Health was listed #4 on the 2015 INC. 500 for large health care companies. Curant Health also received the 2016 Atlanta Business Chronicle Pacesetters Award and the 2016 ACG Fast 40 Award for the fastest growing companies in Atlanta and the State of Georgia. Curant Health’s proprietary Pharmacy Analytics platform MedPlan was a Grand Finalist for Microsoft’s 2013 Excellence Award for Innovation.
Dune Medical is maker of MarginProbe. Dune Medical develops, manufactures, and commercializes innovative products that improve the effectiveness and outcome of cancer therapy by providing real-time tissue characterization systems to guide surgical and diagnostic decisions. The company accomplishes this by identifying significant unmet clinical and market needs and investing in core technologies to develop products that improve patient care, build shareholder value, and create an exciting environment for employees.
Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications. Dune Medical Devices is a privately held company with offices in the U.S. and Israel.
MarginProbe allows surgeons to be able to, in real-time, determine the effectiveness of their lumpectomy excision of a worrisome breast lesion, regarding the presence or absence of tumor cells within the surgical margin. The technology helps reduce the occurrence of having to return to surgery after the pathology results come in reflecting the need for additional excision. Today, as many as 1 in 4 patients must return for more surgery after lumpectomy when this tool is not deployed.
The company has had this tool utilized on over 9000 patients to date and response from clinicians has been overwhelmingly positive.
Marc O’Connor, COO, Curant Health
Lori Chmura, President, Dune Medical Devices